Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

e nine months ended September 30, 2010, Anadys reported a net loss of $13.9 million, compared to $23.0 million for the same period last year.  Basic and diluted net loss per common share was $0.35 for the nine months ended September 30, 2010 compared to $0.71 for the same period last year.Recent Development Program Highlights
  • ANA598 to Advance into Phase IIb.  In October, Anadys announced plans to conduct a Phase IIb study of ANA598 in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) (a current standard of care, or SOC) for the treatment of chronic hepatitis C.  In the planned study, which is on track to commence early in the first quarter of 2011, approximately 200 chronically infected hepatitis C patients are expected to receive ANA598 200 mg bid in combination with SOC, while approximately 66 are to receive placebo and SOC.  Enrollment is expected to include approximately equal numbers of treatment-naïve patients and treatment-experienced patients who have failed a prior course of SOC, including difficult to treat prior null-responders.  Treatment duration for naïve patients will be response-guided, while treatment-experienced patients are to receive all three agents for 48 weeks.  On-treatment response and safety data through 24 weeks is expected in the second half of 2011. Anadys is currently finalizing discussions with the U.S. Food and Drug Administration (FDA) regarding details of the trial design, and plans to conduct the study at a number of sites within and outside the United States.  


  • ANA598 Data at AASLD.  On October 31, 2010, data from the ongoing Phase IIa trial of ANA598 in combination with SOC were presented in an oral presentation at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD).  The presented data showed that ANA598 added to SOC
    '/>"/>


  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/14/2014)... 14, 2014  Invivotek L.L.C., a member of ... announce that its animal research facility was awarded ... and Accreditation of Laboratory Animal Care International (AAALAC). ... science worldwide through voluntary accreditation and assessment programs. ... and use in 38 countries. Invivotek ...
    (Date:7/14/2014)... , July 14, 2014  Remedy Informatics, the ... healthcare delivery and life sciences research, announced that ... Foundation (NPF) to build the first-ever national patient ... cancer and pancreatitis. "The National Pancreas ... change that thoughtful and committed organizations can effect ...
    (Date:7/14/2014)... SAN DIEGO , July 14, 2014  More than ... love their smartphones and tablet computers -- but their eyes ... humans have never needed before, and the eye has not ... lives and what our eyes can do comfortably often results ... symptoms collectively known as Digital Eye Strain. Now ZEISS has ...
    Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3
    ... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today announced ... quarter of fiscal 2011 on Wednesday, May 4. ... financial results and operating activities open to all interested parties ...
    ... 25, 2011 STAAR Surgical Company (NASDAQ: ... minimally invasive ophthalmic lenses for refractive surgery, today announced ... (ICL™) V4c design.  The V4c design incorporates a proprietary ... a size determined to optimize the flow of fluid ...
    Cached Medicine Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 3Visian® ICL and Toric ICL V4c Receive CE Mark Approval 4
    (Date:7/14/2014)... (PRWEB) July 14, 2014 According to the ... is a helpful guide that features a series of new ... in its review that this book can help readers understand ... of high blood pressure, and effective methods to control ... are reviewed now by Vkool, was penned by Ken Burge, ...
    (Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
    (Date:7/14/2014)... July 14, 2014 "Medical devices, tests, ... of us. The Tri-Valley is a star when it ... in the region are working on amazing products and ... face of medicine," according to Dale Kaye CEO of ... showcase some of the brilliant minds and businesses that ...
    (Date:7/14/2014)... July 14, 2014 Reha Technology ... a compact, portable and full-featured upper extremity robotic ... use of interactive games and challenges in a ... Occupational Therapy , Armotion combines a ... order to maximize the therapy effect for patients ...
    (Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
    Breaking Medicine News(10 mins):Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6
    ... Animal Dermatology Clinic,announces the grand opening of their ... in Pasadena, CA. The 3,700 square foot facility ... room, where laser,surgeries, allergy testing, biopsies, and other ... on-site, in a quiet and stress-free,environment. There is ...
    ... 31 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Company"), ... commercialization of novel antibiotics for the,treatment of antibiotic-resistant ... PhD, was honored last night by The,Connecticut Women,s ... & Induction,Ceremony. As part of this year,s event, ...
    ... International has,named John T. Kelly, M.D., Ph.D. as Chief ... to improve the health and,wellness of the users of ... "Our mission is to promote healthier lifestyles and ... "Dr. Kelly will,play a key role in our strategy. ...
    ... Stylish and Sophisticated, Life is Full of,Possibilities and ... Loss., PISCATAWAY, N.J., Oct. 31 Personalizing,solutions for ... Siemens Hearing,Instruments, Inc., a leading manufacturer of hearing ... announcing their new Life,hearing instruments at this year,s ...
    ... from strangers, expert says , , FRIDAY, Oct. 31 (HealthDay ... parents are wondering how they can help keep their ... of pediatric emergency services at Morgan Stanley Children,s Hospital ... make Halloween a happy and safe occasion for everyone. ...
    ... HOUSTON, Oct. 31 Cyberonics, Inc. (Nasdaq:,CYBX) ... Medicaid Services,(CMS) has published the 2009 CMS Outpatient ... Classification (APC) rate for VNS,Therapy. The final rule, ... at $12,545 for insertion of VNS Therapy generators ...
    Cached Medicine News:Health News:Animal Dermatology Clinic Announces Today the Grand Opening of a State of the Art Veterinary Specialty Practice in Pasadena, California 2Health News:Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame 2Health News:Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame 3Health News:Lifeclinic Names Harvard Ph.D. as New Chief Medical Officer 2Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 2Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 3Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 4Health News:Family Halloween Safety Can Be Fiendishly Simple 2Health News:Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS 2Health News:Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS 3
    Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
    Bipolar forceps...
    ... visualize the presence of Human Papilloma Virus (HPV)., ... sample types: tissue, monolayer-based preparations, and conventional Pap. ... The Family 16 probe cocktail has an affinity ... 39, 51, 52, 56, 58, and 66. The ...
    ... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
    Medicine Products: